Physician profile
John N Aaron
NPI 1356650139
$2,957.86
in general payments reported to CMS, 2019-2025
17 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $250 · 2023: $899 · 2024: $853 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,930.28 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $205.40 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $173.47 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $112.30 | 2021-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $104.71 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Dynavax Technologies Corporation | $90.56 | 2021-2024 | Heplisav-B |
| Exact Sciences Corporation | $70.41 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $44.50 | 2024-2025 | |
| Daiichi Sankyo INC. | $37.04 | 2022 | |
| Astellas Pharma US INC | $34.73 | 2023 | Myrbetriq, Veozah |
| Gilead Sciences, INC. | $32.80 | 2021 | |
| Amgen INC. | $31.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.01 | 2023 | Spravato |
| Glaxosmithkline, LLC. | $18.05 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.92 | 2021 | |
| Pfizer INC. | $14.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Aaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.